Latest News
South San Francisco, CA, January 5, 2012 - Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences.
More»
South San Francisco, CA, December 16, 2010 - Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders.
More»
South San Francisco, CA, March 2, 2010 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, today announced the appointment of William J. Dawson to the post of Chief Financial Officer. In this role, Mr. Dawson will be responsible for finance, administration, and business development, reporting to Nassim Usman, Ph.D., Catalyst’s Chief Executive Officer. Mr. Dawson brings more than 30 years of financial management and business development experience to Catalyst.
South San Francisco, CA, July 7, 2009 - Catalyst Biosciences, Inc. today announced the signing of an exclusive worldwide research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop novel engineered proteases that specifically degrade or modulate two targets, one of which will address inflammatory and autoimmune diseases. More»
Collegeville, PA and South San Francisco, CA, June 30, 2009 - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Catalyst Biosciences, Inc. today announced that the two companies have formed an exclusive worldwide collaboration for the discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions. Total payments under the collaboration, including an upfront payment of $21 million, research funding and milestone payments, could exceed $500 million, exclusive of royalty payments.
South San Francisco, CA, March 24, 2009 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, has appointed four new members to the company’s Scientific Advisory Board (SAB). Robert J. Fletterick, Ph.D., David Ginsburg M.D., Guy S. Salvesen, Ph.D., and Gregory Stahl, Ph.D., join initial members Shaun Coughlin, M.D., Ph.D., Charles Craik, Ph.D., and James Wells, Ph.D.
South San Francisco, CA, December 3, 2008 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, has raised $40.4 million in a Series C financing round. New investor Essex Woodlands Health Ventures led the round, with participation from existing investors Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures. More»
South San Francisco, CA, May 6, 2008 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients. Read more»
South San Francisco, CA, January 7, 2008 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, today announced that it has entered into an exclusive worldwide research and license agreement with Centocor Research & Development, Inc. Read more»
Press Coverage
- BioCentury - 1/15/07 (PDF - 668KB)
- BioWorld Today - 1/09/07 (PDF - 147KB)
- BioWorld Today - 2/09/06 (PDF - 142KB)
- Biotech Research Pioneer Appointed to UCSF Faculty - 6/28/05
- BioCentury - 1/17/05 (PDF- 631KB)
- BioWorld Today - 10/29/04 (PDF- 107KB)
- BioCentury - 1/26/04 (PDF - 511KB)
